Cutting-edge clinical cancer research solutions from Illumina deliver the accurate information your lab needs to improve the quality of your reporting and optimize care. Rapidly analyze expert-defined genes and mutation hotspots to find actionable variants in any type of cancer, including solid tumors and hematological malignancies.
Our workflow solutions for translational cancer research include both fixed and customizable cancer panels and a comprehensive range of systems that can be scaled to meet your needs. Our multi-analyte approach enables you to get thorough information efficiently and cost-effectively, even from small specimens. In addition, these integrated solutions include data analysis and reporting capabilities to help you communicate significant findings effectively.
See how the latest advances in genomic technologies can help to identify important mutations in cancer.
Based on the content of TruSight Oncology 500, this proposed in vitro diagnostic will receive prioritized review and resources. Currently in development, the assay is designed to detect known and emerging solid tumor biomarkers.Read Article
TruSight Tumor 170 Panel enables translational researchers to seek answers to multiple questions in one assay.Read Interview
Key opinion leaders discuss the ongoing challenges and potential of NGS in oncology testing.Read Interview
The first liquid biopsy research solution for detecting cancer biomarkers on the NovaSeq 6000 Sequencing System is the latest addition to the Illumina portfolio of comprehensive cancer profiling assays.Read Article
The user-friendly "Recommended Links" feature allows you to easily find content and products relevant to cancer research and/or a variety of other fields. You can access this option from the top of any illumina.com page.Learn How